scispace - formally typeset
R

Rajendra A. Badwe

Researcher at Tata Memorial Hospital

Publications -  168
Citations -  7360

Rajendra A. Badwe is an academic researcher from Tata Memorial Hospital. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 34, co-authored 118 publications receiving 5878 citations. Previous affiliations of Rajendra A. Badwe include Homi Bhabha National Institute.

Papers
More filters
Journal ArticleDOI

Elective versus Therapeutic Neck Dissection in Node-Negative Oral Cancer

TL;DR: Elective node dissection was superior in most subgroups without significant interactions and among patients with early-stage oral squamous-cell cancer, elective neck dissection resulted in higher rates of overall and disease-free survival than did therapeutic neck dissections.
Journal ArticleDOI

Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

TL;DR: Oral neratinib showed substantial clinical activity and was reasonably well tolerated among both heavily pretreated and trastuzumab-naïve patients who had advanced, ErbB2-positive breast cancer.
Journal ArticleDOI

Challenges to effective cancer control in China, India, and Russia

TL;DR: The overall state of health and cancer control in each country is described and additional specific issues for consideration are described: for China, access to care, contamination of the environment, and cancer fatalism and traditional medicine; for India, affordability of care, provision of adequate health personnel, and sociocultural barriers to cancer control.
Journal ArticleDOI

Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial.

TL;DR: In this paper, the authors compared the effect of locoregional treatment with no treatment on outcome in women with metastatic breast cancer at initial presentation, and found that there is no evidence to suggest that the treatment of the primary tumor affects overall survival in patients who have responded to front-line chemotherapy.